A patient-initiated treatment model for blepharospasm and hemifacial spasm: a randomized controlled trial

Sadie Lawes-Wickwar, Hayley McBain, Stefano Brini, Shashivadan P Hirani, Catherine S Hurt, Chris Flood, Nicola Dunlop, Dianne Solly, Bridget Crampton, Stanton P Newman, Daniel G Ezra, Sadie Lawes-Wickwar, Hayley McBain, Stefano Brini, Shashivadan P Hirani, Catherine S Hurt, Chris Flood, Nicola Dunlop, Dianne Solly, Bridget Crampton, Stanton P Newman, Daniel G Ezra

Abstract

Background: To test, in a two-arm, single center, superiority, randomized controlled trial, the effectiveness of and costs associated with a patient-initiated treatment model for people with hemifacial spasm (HFS) and blepharospasm (BEB) in comparison to usual care.

Methods: One hundred and thirty patients with HFS or BEB, aged 18 years or over, were recruited from a nurse-led botulinum toxin type A clinic at an eye hospital in the United Kingdom (UK), completed baseline measures and were randomized (1:1). The intervention group determined their own botulinum toxin type A (BoNT/A) treatment schedule during the trial period (9 months) and received an information leaflet with a "hotline" number to book an appointment. Usual care appointments were scheduled by treating clinicians. Data analysts were blind to study group. The primary outcomes were disease severity and functional disability, as measured by the Jankovic Rating Scale and Blepharospasm Disability Index, respectively. Secondary outcomes included quality of life, anxiety and depression, satisfaction with care, confidence in the service, economic costs and employment days lost.

Results: Sixty-five patients were randomized to each group. The intervention demonstrated no statistically significant difference to usual care for any of primary outcomes. On secondary outcomes the levels of anxiety differed significantly (F2, 142.39 = 1.65, p = 0.02), with the intervention arm exhibiting a decrease and the control arm an increase (Hedges' g = - 0.26 [99% CI -0.83, 0.32]). No other statistically significant differences were found for secondary outcomes. Overall healthcare costs and costs to the patient were on average £198.95 less (95% CI -£256.76, £654.67; p = 0.10) per participant for those in the intervention compared to usual care, although this finding was not significant.

Conclusions: We did not observe differences between the patient-initiated treatment model and usual care for people with BEB or HFS, on any primary outcome measure, quality of life, or depression. The patient-initiated treatment model may, however, have the potential to save healthcare costs and reduce anxiety. Patients using this new model were also equally as satisfied in the service and confident in their care as those receiving treatment as usual.

Trial registration: Clinicaltrials.gov ID NCT02577224 , 16th October 2015.

Keywords: Blepharospasm; Botulinum toxin; Dystonia; Hemifacial spasm; Patient-initiated services; Randomized controlled trial.

Conflict of interest statement

Sadie Lawes-Wickwar, Hayley McBain, Stefano Brini, Shashivadan P. Hirani, Catherine S. Hurt, Chris Flood, Nicola Dunlop, Dianne Solly, Bridget Crampton, Stanton P. Newman and Daniel G. Ezra report no disclosures.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
EMM for HADS Anxiety scores overtime

References

    1. Jinnah HA, Berardelli A, Comella C, et al. The focal dystonias: current views and challenges for future research. Mov Disord. 2013;28:926–943. doi: 10.1002/mds.25567.
    1. Colosimo C, Tiple D, Berardelli A. Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res. 2012;22:265–273. doi: 10.1007/s12640-012-9314-y.
    1. National Health Service . The NHS long term plan. 2019.
    1. Whear R, Abdul-Rahman AK, Thompson-Coon J, Boddy K, Perry MG, Stein K. Patient initiated clinics for patients with chronic or recurrent conditions managed in secondary care: a systematic review of patient reported outcomes and patient and clinician satisfaction. BMC Health Serv Res. 2013;13:501. doi: 10.1186/1472-6963-13-501.
    1. Whear R, Abdul-Rahman AK, Boddy K, Thompson-Coon J, Perry M, Stein K. The clinical effectiveness of patient initiated clinics for patients with chronic or recurrent conditions managed in secondary care: a systematic review. PLoS One. 2013;8:e74774. doi: 10.1371/journal.pone.0074774.
    1. Wickwar S, McBain H, Newman SP, Hirani SP, Hurt C, Dunlop N, et al. Effectiveness and cost-effectiveness of a patient-initiated botulinum toxin treatment model for blepharospasm and hemifacial spasm compared to standard care: study protocol for a randomised controlled trial. Trials. 2016;17:129. doi: 10.1186/s13063-016-1263-y.
    1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.
    1. Jankovic J, Orman J. Botulinum a toxin for cranial-cervical dystonia a double-blind, placebo-controlled study. Neurology. 1987;37:616–623. doi: 10.1212/WNL.37.4.616.
    1. Goertelmeyer S, Brinkmann G, Comes A, Delcker A. The Blepharospasm disability index (BSDI) for the assessment of functional health in focal dystonia. Clin Neurophysiol. 2002;113:S77–S78.
    1. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S, NT 201 Blepharospasm Study Team Efficacy and safety of a new botulinum toxin type a free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–312. doi: 10.1007/s00702-005-0323-3.
    1. Attkisson CC, Zwick R. The client satisfaction questionnaire: psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5:233–237. doi: 10.1016/0149-7189(82)90074-X.
    1. Müller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry. 2004;75:749–753. doi: 10.1136/jnnp.2003.013441.
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x.
    1. Curtis L, Burns A. Unit costs of health and social care 2015. Canterbury: Personal Social Services Research Unit; 2015.
    1. Curtis L. Unit costs of health and social care 2014. Canterbury: Personal Social Services Research Unit; 2014.
    1. Curtis, Burns A. Unit costs of Health & Social Care. Canterbury: Personal Social Services Research Unit, University of Kent; 2013.
    1. Department of Health and Social Care. (2016). NHS reference costs 2015 to 2016. Department of Health and Social Care.
    1. National Institute for Health and Care Excellence (NICE). [Website] UK [Accessed June 2019]. Available from:
    1. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editor. Measuring mental health needs, Gaskell. 2. 2001. pp. 200–224.
    1. Rubin DB. Multiple imputation for nonresponse in surveys. Hoboken: Wiley; 2009.
    1. Turner HM, Bernard RM. Calculating and synthesizing effect sizes. Contemp Issues Commun Sci Disord. 2006;33:42–55. doi: 10.1044/cicsd_33_S_42.
    1. Maas CJ, Hox JJ. Sufficient sample sizes for multilevel modeling. Methodology. 2005;1(3):85–91. doi: 10.1027/1614-2241.1.3.85.
    1. McBain H, Shipley M, Moore S, Olaleye A, Hirani S, Newman SP. A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomized controlled trial. Ann Rheum Dis. 2015:1–7. 10.1136/annrheumdis-2015-207768.
    1. Whear R, Thompson-Coon J, Rogers M, Abbott RA, Anderson L, Ukoumunne O, et al. Patient-initiated appointment systems for adults with chronic conditions in secondary care. Cochrane Database Syst Rev. 2020;4(4):CD010763.
    1. Tucha O, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand. 2001;103(1):49–52. doi: 10.1034/j.1600-0404.2001.00109.x.
    1. Hewlett S, Mitchell K, Haynes J, Paine T, Korendowych E. Kirwan JR. Patient-initiated hospital follow-up for rheumatoid arthritis. Rheumatology 2000:39:990-997.
    1. Hewlett S, Kirwan J, Pollock J, Mitchell K, Hehir M, Blair PS, et al. Patient initiated outpatient follow up in rheumatoid arthritis: six year randomised controlled trial. BMJ. 2005;330:171. doi: 10.1136/bmj.38265.493773.8F.
    1. Trappenburg J, Jonkman N, Jaarsma T, et al. Self-management: one size does not fit all. Patient Educ Couns. 2013;92:134–137. doi: 10.1016/j.pec.2013.02.009.
    1. Kirwan JR, Mitchell K, Hewlett S, et al. Clinical and psychological outcome from a randomised controlled trial of patient-initiated direct-access hospital follow-up for rheumatoid arthritis extended to 4 years. Rheumatology (Oxford) 2003;42:422–426. doi: 10.1093/rheumatology/keg130.
    1. Sanders C, Rogers A, Bowen R, et al. Exploring barriers to participation and adoption of telehealth and telecare within the whole system demonstrator trial: a qualitative study. BMC Health Serv Res. 2012;12:220. doi: 10.1186/1472-6963-12-220.
    1. Sethi K, Fezza J, Burns J, Woodward J, Truong D, Hedges T, et al. A structured interview evaluating Botulinum toxin type a treatments for blepharospasm. Neurology. 2015;84(14 Supplement):P4.328.
    1. Child S, Goodwin VA, Perry MG, Gericke CA, Byng R. Implementing a patient-initiated review system in rheumatoid arthritis: a qualitative evaluation. BMC Health Serv Res. 2015;15:157. doi: 10.1186/s12913-015-0837-9.
    1. Sekhon M, Cartwright M, Lawes-Wickwar S, McBain H, Newman SP, Ezra DG, et al. Does prospective acceptability of an intervention influence refusal to participate in a randomised controlled trial? An interview study. Contemp Clin Trials Commun. 2021;21:100698. doi: 10.1016/j.conctc.2021.100698.
    1. Moher D, Pham B, Jones A, et al. Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352:609–613. doi: 10.1016/S0140-6736(98)01085-X.
    1. Pildal J, Hrobjartsson A, Jörgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36:847–857. doi: 10.1093/ije/dym087.
    1. Wabbels B, Roggenkämper P. Botulinum toxin in hemifacial spasm: the challenge to assess the effect of treatment. J Neural Transm. 2012;119(8):963–980. doi: 10.1007/s00702-011-0762-y.
    1. Wabbels B, Reichel G, Fulford-Smith A, Wright N, Roggenkämper P. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type a products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233–239. doi: 10.1007/s00702-010-0529-x.
    1. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. 2009;37:3114–3119. doi: 10.1097/CCM.0b013e3181bc7bd5.
    1. Bafeta A, Dechartres A, Trinquart L, Yavchitz A, Boutron I, Ravaud P. Impact of single Centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study. BMJ. 2012;344:e813. doi: 10.1136/bmj.e813.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren